Drug-susceptibility tests in tuberculosis: contradictory or neglected?

Authors

  • João Victor Soares Coriolano Coutinho Hospital Estadual de Doenças Tropicais Dr. Anuar Auad (HDT), Ambulatório de Micobactérias - Goiânia - Goiás - Brasil.
  • Taiguara Fraga Guimarães Pontifícia Universidade Católica de Goiás (PUC-GO), Curso de Medicina - Goiânia - Goiás - Brasil.
  • Renata de Bastos Ascenço Soares Pontifícia Universidade Católica de Goiás (PUC-GO), Curso de Medicina - Goiânia - Goiás - Brasil.

DOI:

https://doi.org/10.5935/2764-734X.e20250459

Keywords:

Tuberculosis, Multidrug-Resistant, Real-Time Polymerase Chain Reaction, Genetic Testing, Case Reports

Abstract

Tuberculosis continues to have a negative impact on public health, especially its multidrug-resistant variant. Consequently, rapid molecular tests are used to identify the genetic mutations responsible for resistance to the first- and second-line drugs used for treatment. However, these tests have detection limitations in some clinical cases. Therefore, all available information must be collected and validated. Here, we report a case where the laboratory results showed discrepancies between molecular and phenotypic methods—an aspect that had not been considered in the case’s conclusion. This led to the discussion regarding noncompliance with established clinical care algorithms, which deserve to be revisited.

References

1. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde e Ambiente. Boletim Epidemiológico da Tuberculose. Brasília: Ministério da Saúde; 2023 [acesso 2025 mar 29]. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/boletins/epidemiologicos/especiais/2023/boletim-epidemiologico-de-tuberculose-numero-especial-mar.2023/view

2. Chakravorty S, Simmons AM, Rowneki M, Parmar H, Cao Y, Ryan J, et al. The New Xpert MTB/RIF Ultra: Improving Detection of Mycobacterium tuberculosis and Resistance to Rifampin in an Assay Suitable for Point-of-Care Testing. mBio. 2017 Aug 29;8(4):e00812-7. DOI: 10.1128/mBio.00812-17

3. Domínguez EC, Boettger D, Cirillo, F, Cabelens F, Eisenach KD, Gagneux S, et al; TBNET; RESIST-TB networks. Clinical implications of molecular drug resistance testing for Mycobacterium tuberculosis: a TBNET/RESISTENT-TB consensus statement. Int J Tuberc Lung Dis. 2016 Jan;20(1):24-42. DOI: 10.5588/ijtld.15.0221

4. Brasil. Ministério da Saúde. Departamento de HIV/Aids, Tuberculose, Hepatites Virais e Infecções Sexualmente Transmissíveis. Recomendações técnicas para laudo e interpretação do teste de hibridização em linha (Line Probe Assay - LPA) para tuberculose. Brasília: Ministério da Saúde; 2023 [acesso 2025 mar 20]. Disponível em: https://www.gov.br/aids/pt-br/central-de-conteudo/publicacoes/2023/recomendacoes-tecnicas-para-laudo-e-interpretacao-do-teste-de-hibridizacao-com-sonda-em-linha-line-probe-assay-lpa-para-tuberc.pdf/view

5. Chan ACK, Chan MCH, Yip PCW, Yam WC, Chau CH, Lam RFM, et al. Grave impact of undetected rpoB I572F mutation on clinical course of multidrug-resistant tuberculosis: a case report. Hong Kong Med J. 2023 Feb;29(1):70-2. DOI: 10.12809/hkmj219735

6. Brasil. Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Vigilância das Doenças Transmissíveis. Manual de recomendações para o controle da Tuberculose no Brasil. 2ª ed. Brasília: Ministério da Saúde; 2019 [acesso 2025 mar 29]. Disponível em: https://www.gov.br/saude/pt-br/centrais-de-conteudo/publicacoes/svsa/tuberculose/manual-de-recomendacoes-e-controle-da-tuberculose-no-brasil-2a-ed.pdf/view

7. André E, Goeminne L, Colmant U, Berckert P, Niemann S, Delmee M. Novel rapid PCR or the detection of lle491Phe rpoB mutation of Mycobacterium tuberculosis, a rifampicin-resistance-conferring mutation undetected by commercial assays. Clin Microbiol Infect. 2017 Apr;23(4):267.e5-267.e7. DOI: 10.1016/j.cmi.2016.12.009

8. Alves KKAF, Borralho LM, Araújo AJ, Bernardino IM, Figueiredo TMRM. Fatores associados à cura e ao abandono do tratamento da tuberculose na população privada de liberdade. Rev Bras Epidemiol. 2020;23:e200079. DOI: 10.1590/1980-549720200079

9. Lôbo NMN, Portela MC, Sanchez AAMM. Análise do cuidado em saúde no sistema prisional do Pará, Brasil. Ciênc Saúde Coletiva. 2022 Dez;27(12):4423-34. DOI: 10.1590/1413-812320222712.10212022

10. Rocha MS, Bartholomay P, Cavalcante MV, Medeiros FC, Codenotti SB, Pelissari DM, et al. Notifiable Diseases Information System (SINAN): main features of tuberculosis-related notification and data analysis. Epidemiol Serv Saude. 2020 Feb 17;29(1):e2019017. DOI: 10.5123/S1679-49742020000100009

11. Liu YE, Mabene Y, Camelo S, Rueda ZV, Pelissari DM, Dockhorn Costa Johansen F, et al. Mass incarceration as a driver of the tuberculosis epidemic in Latin America and projected effects of policy alternatives: a mathematical modelling study. Lancet Public Health. 2024 Nov;9(11):e841-e51. DOI: 10.1016/S2468-2667(24)00192-0

Downloads

Published

2025-05-23

How to Cite

Coutinho, J. V. S. C., Guimarães, T. F., & Soares, R. de B. A. (2025). Drug-susceptibility tests in tuberculosis: contradictory or neglected?. Infections in Evidence, 4, e20250459. https://doi.org/10.5935/2764-734X.e20250459

Issue

Vol. 4 (2025)

Section

Case Reports

License

Copyright (c) 2025 Infections in Evidence

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

The Copyright Transfer Agreement assumes that the authors are the legitimate holders of the copyright of the Case Report in question, without infringing any copyright, trademark or patent of others. In this way, they transfer all rights to this manuscript or any revision, version or translation of it to the Journal, including here the exclusivity of its eventual commercialization, provided that in accordance with ethical and moral precepts and relevant Brazilian legislation. All articles in the INFECTIONS IN EVIDENCE Journal are published under the terms of international license 4.0 of the Creative Commons Attribution, which allows users to freely read, download, share and adapt cultural and scientific productions, provided that due credit is given to the original authors and publication.
The Copyright Transfer Agreement also understands that the authors guarantee that the respective Case Report has never been published in another communication vehicle or scientific journal. Papers presented at meetings and/or scientific congresses may be published in the electronic journal INFECTIOUS DISEASES IN EVIDENCE - Case Reports, provided that they have not been published in whole or in part in their Proceedings or Annals.